Loading…
Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.
Biotech developing complement-pathway inhibitors (narsoplimab) for rare blood and transplant-related diseases.
Has no product of its own on sale after selling its Omidria eye-surgery drug in 2021, so it funds development from capital it raises and from deals tied to that sale. Revenue from narsoplimab would start only if regulators approve it.
Moat: narrow (IP / patents). MASP-2-targeted mechanism is differentiated from complement C5 inhibitors used by rivals.
Headquarters: Seattle, Washington, US · Founded: 1994 · Employees: 175
Size Omeros (OMER) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.22B, the 2127th largest of 3,117 United States companies the cockpit tracks. Shares closed at $16.92 on 6 Nov 2026.
Performance Over six months the shares gained 14.1%, against -8.1% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth The operating margin is -189.5% (peer median 4.5%).
Valuation It trades at 7.7× forward earnings against a peer median of 19.6× (2nd cheapest of 10).
Capital Return on invested capital runs 67.6 points below its cost of capital (16.9% WACC).
Short interest Short interest is 15.8% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $38.4M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $36.1M | -$964,000 | -$950,000 | -$920,000 | -$952,000 |
| EBITDA | -$71.9M | -$122M | -$168M | -$164M | -$162M |
| Net income | $125M | -$3.35M | -$157M | -$118M | $47.4M |
| Free cash flow | -$75.1M | -$123M | -$149M | $74.3M | -$86.6M |
| Capital expenditure | $56,000 | $65,000 | $165,000 | $426,000 | $113,000 |
| Total debt | $297M | $407M | $423M | $362M | $468M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Omeros OMER | $1.22B | +14% | n/a | -190% | 7.7× | n/a |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 18.3× | 14.5% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 9.6× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OMER | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.5% | -2.4% | 7th lowest of 21 |
| 6-month return | +14.1% | -8.1% | 6th highest of 21 |
| Distance from 52-week high | -20.3% | -33.8% | 3rd highest of 21 |
| Operating margin | -189.5% | 4.5% | 5th lowest of 17 |
| Forward P/E | 7.7× | 19.6× | 2nd cheapest of 10 |
| ROIC minus cost of capital | -67.6 pp | -3.3 pp | 4th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | n/a | 11.7% | +18.1% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | n/a | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |